Clinical trials: Neurogenic Detrusor Overactivity
Overactive Detrusor, Neurogenic Bladder
Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder
This study will evaluate the safety and efficacy of Oxybutynin Chloride 10% Topical Gel in children 3 to less than 17 years old, who have overactive bladder due to a neurogenic condition.
- Trial name
- NCT01192568
- Testing
- Oxybutynin
- Where
- 10 sites in United States
- Volunteers
- 52 people
- Sponsor
- AbbVie
Neurogenic Detrusor Overactivity, Spinal Cord Injury
Treatment of Neurogenic Detrusor Overactivity: Early Versus Late Pudendal Nerve Stimulation in Spinal Cord Injury (SCI) Patients
Background: Although a small group, special attention has to be given to lower urinary tract (LUT) dysfunctions in spinal cord injury (SCI) patients, as they also suffer under a loss of motor-sensory function and autonomic…
- Trial name
- NCT01043848
- Testing
- external electric pudendal nerve stimulation
- Where
- 3 sites in Spain, Switzerland
- Sponsor
- Ulrich Mehnert
Multiple Sclerosis, Overactive Detrusor
Study of Darifenacin in Patients Suffering From Multiple Sclerosis and Neurogenic Detrusor Overactivity
The objective of this study is to explore the effects of darifenacin in patients with multiple sclerosis and neurogenic detrusor overactivity.
- Trial name
- NCT00845338
- Testing
- Darifenacin (BAY79-4998)
- Where
- 15 sites in Germany
- Volunteers
- 7 people
- Sponsor
- Bayer
Spinal Cord Injury, Detrusor Overacitivity
Effects of Sacral and Tibial Stimulation on Bladder Function in Subacute Suprasacral Spinal Cord Injury
Suprasacral spinal cord injury (SCI) frequently leads to neurogenic detrusor overactivity (NDO), resulting in elevated bladder storage pressures, urinary incontinence, and an increased risk of upper urinary tract damage.
- Trial name
- NCT07343583
- Testing
- Transcutaneous Tibial Nerve Stimulation, Transcutaneous Sacral Nerve Stimulation
- Where
- Turkey (Türkiye)
- Volunteers
- 45 people
- Sponsor
- Ankara City Hospital Bilkent
Detrusor Hyperreflexia
A Study Evaluating Oxybutynin in Patients With Neurogenic Overactive Bladder Associated With a Neurological Condition
This study will evaluate the efficacy and safety of an anticholinergic drug treatment administered by transdermal patch to treat overactive bladder in adults who have spinal cord injury.
- Trial name
- NCT00224029
- Testing
- Oxybutynin transdermal system
- Where
- 6 sites in United States
- Volunteers
- 24 people
- Sponsor
- Watson Pharmaceuticals
Urinary Incontinence, Urinary Bladder, Neurogenic
Feasibility of Triggered Sacral Neuromodulation for Neurogenic Bladder
Incontinence associates with military service and post-traumatic stress disorder in both male and female Veterans. Neurogenic detrusor overactivity (NDO) is caused by spinal cord injury or disorder, or peripheral…
- Trial name
- NCT05141487
- Testing
- UroMonitor, ASCU
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- VA Office of Research and Development
Overactive Bladder Syndrome
Overactive Bladder Syndrome: Incobotulinumtoxin Versus Onabotulinumtoxin
The aim of the original study was to compare Incobot/A versus Onabot/A in order to evaluate if the differences in the pharmacologic formulations between the two drugs could affect their efficacy and safety in the treatment of…
- Trial name
- NCT03758235
- Testing
- IncobotulinumtoxinA 100 UNT Injection [Xeomin], OnabotulinumtoxinA 100 UNT [Botox]
- Where
- Italy
- Volunteers
- 140 people
- Sponsor
- University Of Perugia
Detrusor Hyperreflexia
Safety and Efficacy Study of Transdermal Oxybutynin to Treat Overactive Bladder With a Neurological Condition
This study will evaluate the safety and effectiveness of an anticholinergic drug treatment administered by transdermal patch to treat overactive bladder in children who have a neurological condition (e.g.
- Trial name
- NCT00224016
- Testing
- Oxybutynin
- Where
- 23 sites in United States
- Volunteers
- 57 people
- Sponsor
- Watson Pharmaceuticals
Overactive Bladder
OnabotulinumtoxinA (onaBoNT-A) Versus Oral Oxybutynin ER
Overactive bladder is a condition associated with symptoms of feeling the urge to urinate, urinating often, and may or may not be accompanied by leakage of urine.
- Trial name
- NCT01050114
- Testing
- onaBoNT-A, Oxybutynin ER
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Christopher Patrick Smith
Neurogenic Bladder
Device for Bladder Control for Men With SCI
Urinary incontinence, bladder frequency, and bladder urgency are significant medical problems for people with overactive bladder (OAB) or neurogenic bladder overactivity (NDO).
- Trial name
- NCT07668063
- Testing
- Noninvasive electrical stimulation device to improve bladder control
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- VA Office of Research and Development
Urinary Bladder, Neurogenic
Open-label Long-term Extension Study of Fesoterodine in Japanese Subjects With Neurogenic Detrusor Overactivity.
The purpose of this study is to investigate the safety and tolerability of fesoterodine following once daily long-term treatment in Japanese pediatric neurogenic detrusor overactivity (NDO) subjects.
- Trial name
- NCT02501928
- Testing
- Fesoterodine PR 4 mg, Fesoterodine PR 8 mg, Fesoterodine BIC 2 mg
- Where
- 7 sites in Japan
- Volunteers
- 12 people
- Sponsor
- Pfizer
Mild Cognitive Impairment, Spinal Cord Injuries
Effects of Antimuscarinics on Cognition in Spinal Cord Injury
Prospective evaluation of the cognitive function of in-house patients suffering from an acute traumatic spinal cord injury before and three months after the initiation of antimuscarinic treatment.
- Trial name
- NCT01600404
- Testing
- antimuscarinic treatment
- Where
- Switzerland
- Volunteers
- 32 people
- Sponsor
- Swiss Paraplegic Research, Nottwil
Neurogenic Detrusor Overactivity, Spinal Cord Injuries
Dose Escalation Study of EG110A, Administered by Intradetrusor Injections to Adults With Neurogenic Detrusor Overactivity-related Incontinence Following Spinal Cord Injury Who Regularly Perform Clean Intermittent Catheterization
This is a first-in-human, Phase 1b/2a, open-label, dose-escalation study of a single treatment course consisting of multiple intradetrusor injections of EG110A in male and female adult participants with Neurogenic Detrusor…
- Trial name
- NCT06596291
- Testing
- EG110A
- Where
- 5 sites in United States
- Volunteers
- 16 people
- Sponsor
- Cyllene Therapeutics
Urinary Incontinence, Overactive Bladder
Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 1
The purpose of this study is to provide confirmatory evidence of the safety and efficacy of two Dysport® (AbobotulinumtoxinA) doses (600 units [U] and 800 U), compared to placebo in reducing urinary incontinence (UI) in adult…
- Trial name
- CONTENT1 (NCT02660138)
- Testing
- Botulinum toxin type A
- Where
- 81 sites in United States, Canada and 8 more
- Volunteers
- 227 people
- Sponsor
- Ipsen
Spinal Cord Injury, Neurogenic Detrusor Overactivity
Comparative Study of the Efficacy and Safety of Muscarinic M3 Receptors Antagonists in the Treatment of Neurogenic Detrusor Overactivity
This is a phase IV, double-blind, multicenter, randomized trial evaluating the efficacy and safety of two M3 receptors antagonists (Trospium Chloride and Darifenacin Hydrobromide) with one standard drug (Oxybutynin Chloride) for…
- Trial name
- NCT00800462
- Testing
- Oxybutynin Cl, Trospium Cl, Darifenacin Hydrogen Bromide (HBr)
- Where
- 2 sites in Canada
- Volunteers
- 23 people
- Sponsor
- Toronto Rehabilitation Institute
Spinal Dysraphism
Determining Developmental and Clinical Markers Affecting Urinary Function of Children With Spinal Dysraphism
To identify developmental and clinical biomarkers that affect urinary incontinence at the ages of 5, 7, and 10 according to different neuro-urological clinical factors.
- Trial name
- NCT05962086
- Where
- 6 sites in South Korea
- Volunteers
- 1,500 people
- Sponsor
- Seoul National University Hospital
Neurogenic Detrusor Overactivity, Pediatric
A Clinical Study to Investigate How Solifenacin Fluid is Taken up, How Long it Stays in the Body and How Effective and Safe it is in Treating Children Aged From 6 Months to Less Than 5 Years With Symptoms of Neurogenic Detrusor Overactivity (NDO)
The purpose of this study was to evaluate long term efficacy and safety of treatment with solifenacin succinate (the study drug) in children with neurogenic detrusor overactivity after multiple dose administration.
- Trial name
- NCT01981954
- Testing
- Solifenacin succinate
- Where
- 8 sites in United States, Belgium and 4 more
- Volunteers
- 23 people
- Sponsor
- Astellas Pharma Europe B.V.
Neurogenic Detrusor Overactivity
Study To Assess The Bioequivalence Under Fed And Fasted Conditions Of The Fesoterodine Beads-In-Capsule SR4 And SR7 Formulations And To Estimate The Bioavailability of SR7 Beads Sprinkled On Apple Sauce Relative To The Beads-In-Capsule SR7 Formulation Administer
Open Label, Single-Dose, Crossover Study To Assess The Bioequivalence Under Fed And Fasted Conditions Of The Fesoterodine Beads-In-Capsule (BIC) SR4 And SR7 Formulations And To Estimate The Bioavailability of SR7 Beads Sprinkled…
- Trial name
- NCT04452838
- Testing
- Fesoterodine BIC SR4 fasted (Treatment A in Part A, Treatment G in Part B), Fesoterodine BIC SR7 fasted (Treatment B in Part A, Treatment H in Part B), Fesoterodine BIC SR7 fed (Treatment C in Part A, Treatment F in Part B)
- Where
- Belgium
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Pfizer
Neurogenic Bladder, Detrusor Underactivity
A Comparative Analysis of Portable Bladder Scanner to Determine Age/ Volume Specific Accuracy in 0-6 Years of Children
As a part of the urodynamic studies, urinary catheterization is inserted to measure residual urine, however, it has shown to be an invasive procedure, cause urinary tract infection, and traumatic experience.
- Conditions
- Neurogenic Bladder, Detrusor Underactivity, Detrusor Overactivity
- Trial name
- NCT04543552
- Testing
- Bladder scan
- Where
- South Korea
- Volunteers
- 34 people
- Sponsor
- Seoul National University Hospital
Urinary Incontinence
Study of OnabotulinumtoxinA (BOTOX®) for Urinary Incontinence Due to Neurogenic Detrusor Overactivity in Pediatric Patients
This study will evaluate the 3 doses of onabotulinumtoxinA (botulinum toxin Type A) for the treatment of urinary incontinence due to neurogenic detrusor overactivity in pediatric participants between the ages of 5 to 17 years to…
- Trial name
- NCT01852045
- Testing
- OnabotulinumtoxinA
- Where
- 31 sites in United States, Belgium and 6 more
- Volunteers
- 114 people
- Sponsor
- Allergan